Eli Lilly's most recent trend suggests a bullish bias. One trading opportunity on Eli Lilly is a Bull Put Spread using a strike $65.50 short put and a strike $60.50 long put offers a potential 18.76% return on risk over the next 26 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $65.50 by expiration. The full premium credit of $0.79 would be kept by the premium seller. The risk of $4.21 would be incurred if the stock dropped below the $60.50 long put strike price.
The 5-day moving average is moving up which suggests that the short-term momentum for Eli Lilly is bullish and the probability of a rise in share price is higher if the stock starts trending.
The 20-day moving average is moving up which suggests that the medium-term momentum for Eli Lilly is bullish.
The RSI indicator is at 60.62 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Eli Lilly
[$$] Judge Cuts Damages Takeda, Lilly to Pay in Actos Case
Tue, 28 Oct 2014 00:42:10 GMT
The Top Stocks to Watch in Asia Today
Tue, 28 Oct 2014 00:13:18 GMT
Lilly Responds to Decision in Case of Terrence Allen, et al. v. Takeda
Mon, 27 Oct 2014 23:45:00 GMT
PR Newswire – INDIANAPOLIS, Oct. 27, 2014 /PRNewswire/ — Eli Lilly and Company (LLY) issued the following statement today in response to a judge's ruling that the punitive damages awarded in the case of Terrence Allen, et al. v. Takeda Pharmaceuticals North America, Inc., et al, No. 6:12-cv-00064 be reduced. The judge in the Louisiana multidistrict litigation trial reduced the punitive damages from $3 billion for Lilly and $6 billion for Takeda to $9.2 million for Lilly and $27.6 million for Takeda. Plaintiffs also were awarded $1.27 million in compensatory damages. “While we have empathy for the plaintiff, we believe the evidence did not support his claims,” said Mike Harrington, senior vice president and general counsel, Lilly. “We will continue working vigorously to overturn the verdict.”
Damage award sharply cut in Takeda, Lilly case over diabetes drug
Mon, 27 Oct 2014 23:43:42 GMT
U.S. judge pares $9 bln award against Takeda, Eli Lilly over drug
Mon, 27 Oct 2014 20:19:09 GMT
Also on Market Tamer…
Follow Us on Facebook